Gain Therapeutics, Inc.
GANX
$1.65
-$0.04-2.37%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -4.54M | -5.28M | -5.81M | -4.53M | -3.77M |
| Total Depreciation and Amortization | 15.20K | 10.80K | 9.30K | 9.70K | 9.30K |
| Total Amortization of Deferred Charges | 13.00K | 12.00K | 13.00K | 11.00K | 12.00K |
| Total Other Non-Cash Items | 412.90K | 470.90K | 1.20M | 529.10K | 913.30K |
| Change in Net Operating Assets | -522.00K | -135.70K | -507.50K | 158.80K | -621.00K |
| Cash from Operations | -4.62M | -4.93M | -5.10M | -3.82M | -3.45M |
| Capital Expenditure | -- | -- | -- | -- | -900.00 |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -42.50K |
| Cash from Investing | -- | -- | -- | -- | -43.40K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -25.00K | -25.00K | -24.20K | -22.20K | -22.80K |
| Issuance of Common Stock | 16.58M | 7.45M | 2.49M | 2.42M | 2.34M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | -395.50K | -- | -- | 0.00 |
| Cash from Financing | 16.55M | 7.03M | 2.47M | 2.40M | 2.31M |
| Foreign Exchange rate Adjustments | 97.80K | 6.70K | 260.10K | 109.50K | -480.60K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 12.03M | 2.11M | -2.37M | -1.31M | -1.67M |